FacebookLinkedInRssXYouTube

Esperion Therapeutics

Esperion Sees Positive Results From Final Study On Cholesterol-Buster

ANN ARBOR — Esperion Therapeutics Inc., the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedoic acid. The company said a global, pivotal Phase 3 clinical study (Study 1002-047) showed that a dose of 180 milligrams per day of the drug showed additional lowering of

By |2018-10-31T19:37:08-04:00October 31st, 2018|ESD, Life Sciences|
Read More

Esperion Therapeutics Files Initial Public Offering For $150 Million

ANN ARBOR — The cholesterol-fighting drug developer Esperion Therapeutics Tuesday announced an initial public offering of $150 million of its common stock. Esperion also expects to grant the underwriters a 30-day option to purchase up to $22.5 million of additional shares of its common stock. The company said it would use the net proceeds of

By |2017-08-08T22:12:44-04:00August 8th, 2017|Entrepreneur, Entrepreneurs, Life Sciences|
Read More